Catalent Stock Forecast, Price & News

+1.82 (+1.51 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume709,488 shs
Average Volume968,712 shs
Market Capitalization$20.81 billion
P/E Ratio41.13
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

Catalent logo

About Catalent

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.02 out of 5 stars

Medical Sector

550th out of 1,309 stocks

Pharmaceutical Preparations Industry

278th out of 646 stocks

Analyst Opinion: 1.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Catalent (NYSE:CTLT) Frequently Asked Questions

Is Catalent a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Catalent stock.
View analyst ratings for Catalent
or view top-rated stocks.

What stocks does MarketBeat like better than Catalent?

Wall Street analysts have given Catalent a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Catalent wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Monday, August 30th 2021.
View our earnings forecast for Catalent

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) released its quarterly earnings results on Tuesday, May, 4th. The company reported $0.82 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.74 by $0.08. The firm earned $1.05 billion during the quarter, compared to analyst estimates of $994.28 million. Catalent had a net margin of 14.43% and a trailing twelve-month return on equity of 13.88%. The firm's revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.50 earnings per share.
View Catalent's earnings history

How has Catalent's stock been impacted by COVID-19 (Coronavirus)?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTLT shares have increased by 165.3% and is now trading at $122.16.
View which stocks have been most impacted by COVID-19

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2021 earnings guidance on Tuesday, May, 18th. The company provided earnings per share (EPS) guidance of 2.780-2.970 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.830. The company issued revenue guidance of $3.88 billion-$3.98 billion, compared to the consensus revenue estimate of $3.89 billion.

What price target have analysts set for CTLT?

8 brokerages have issued twelve-month price targets for Catalent's stock. Their forecasts range from $100.00 to $140.00. On average, they expect Catalent's share price to reach $125.13 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts' price targets for Catalent
or view top-rated stocks among Wall Street analysts.

Who are Catalent's key executives?

Catalent's management team includes the following people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 57, Pay $2.53M)
  • Mr. Alessandro Maselli, Pres & COO (Age 49, Pay $2.09M)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $1.09M)
  • Ms. Karen A. Flynn, Pres of Biologics & Chief Commercial Officer (Age 58, Pay $665.37k)
  • Mr. Thomas P. Castellano, Sr. VP & CFO (Age 41)
  • Mr. Ricky Hopson, VP & Chief Accounting Officer (Age 45)
  • Mr. Julien Meissonnier, VP & Chief Scientific Officer
  • Mr. Paul Surdez, VP of Investor Relations
  • Mr. Michael J. Grippo, Sr. VP of Strategy & Corp. Devel. (Age 52)
  • Mr. Ricardo Pravda, Sr. VP & Chief HR Officer (Age 49)

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent CEO John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among Catalent's employees.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of retail and institutional investors. Top institutional investors include Veritas Asset Management LLP (3.11%), New York State Common Retirement Fund (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.31%), Tran Capital Management L.P. (0.31%), Alliancebernstein L.P. (0.13%) and Kornitzer Capital Management Inc. KS (0.13%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano and Wetteny Joseph.
View institutional ownership trends for Catalent

Which institutional investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware, Sumitomo Mitsui Trust Holdings Inc., Oregon Public Employees Retirement Fund, Advisor Group Holdings Inc., Kornitzer Capital Management Inc. KS, Vigilant Capital Management LLC, Handelsbanken Fonder AB, and Victory Capital Management Inc.. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Thomas P Castellano, and Wetteny Joseph.
View insider buying and selling activity for Catalent
or view top insider-selling stocks.

Which institutional investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Brinker Capital Investments LLC, Tran Capital Management L.P., NZS Capital LLC, Advisors Capital Management LLC, IFM Investors Pty Ltd, North Star Asset Management Inc., and Exchange Traded Concepts LLC.
View insider buying and selling activity for Catalent
or or view top insider-buying stocks.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $122.16.

How much money does Catalent make?

Catalent has a market capitalization of $20.81 billion and generates $3.09 billion in revenue each year. The company earns $173 million in net income (profit) each year or $1.88 on an earnings per share basis.

How many employees does Catalent have?

Catalent employs 13,900 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

Where are Catalent's headquarters?

Catalent is headquartered at 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]

This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.